In 2018, Mark Tassinari was living in a Salvation Army rehabilitation center in Massachusetts, taking buprenorphine that a doctor had prescribed for his opioid use disorder. The program found out and discharged him. According to the federal judge who later let his lawsuit go forward, Tassinari “suffered housing instability and a relapse” after he was put out. In 2021 he tried to get back in. He was turned away again, for the same prescription. His lawyer told STAT that each of the Salvation Army’s adult recovery centers in the Northeast was turning away 10 to 20 people a week on the same grounds.
Hold Tassinari in mind as you read this morning’s news. STAT’s Theresa Gaffney reports that Health Secretary Robert F. Kennedy Jr. wants federal money flowing to faith-based recovery programs, the kind that have mostly lived on donations and church budgets. The model he toured in October is Sheepgate, a Christian center in Colfax, Iowa. Sheepgate bans methadone. It allows Suboxone only if the resident is fully tapered off within three months.
A program that makes you quit the medicine keeping you alive in order to keep your bed is not offering recovery. It is offering a deadline.
Faith is not the problem here. Plenty of people got sober in church basements, and Kennedy credits his own recovery to AA and his Catholic faith. The problem is a stopwatch, and Washington has spent this year building one into its grant rules.
The quiet part is in the grant paperwork, not the speeches
The speeches are about faith. The paperwork is about medication. On April 24, SAMHSA’s principal deputy assistant secretary, Christopher Carroll, sent grantees a Dear Colleague letter on medications for opioid use disorder. It says SAMHSA wants medications to be part of the path to recovery, “not as a default sentence to life-long medication use.” It tells grantees that, at least once a year, clinicians should talk with each patient about whether to keep taking the medication. It says SAMHSA money can pay for “tapering and discontinuation” (gradually lowering the dose until you stop). STAT reports that this guidance is now written into SAMHSA’s standard terms and conditions for every grant recipient, dated June 3.
Read the whole letter and it is more careful than its headline phrase. It says the decision to stop should be shared between patient and clinician, gradual, and “done in the context of ongoing” care. It even concedes that “arbitrary maximum time limits or abrupt discontinuation of treatment can result in poor outcomes for patients.” That sentence is the best thing in the document. It describes Sheepgate’s three-month rule almost exactly, and calls it bad medicine.
But words in a funding letter don’t stay fine print. Calling long-term treatment a “sentence” tells every program director who reads it which way the agency leans. Health Affairs Forefront argued the language implies people stay on medication longer than helps them, when the evidence points the other way. Filter’s Helen Redmond called it an anti-medication bias dressed as patient choice. Redmond also documented the opposite problem, and it deserves to be taken seriously. Bill Kinkle, a nurse who took methadone for years, told her that when he decided to taper, “There was major pressure to stay on indefinitely.” A clinic that won’t let you leave is also a clinic that isn’t listening. The answer to that is a patient who decides, not a grant term that leans on the scale.
Now put the letter next to Kennedy’s push. HHS has already handed out $500,000 supplemental awards for faith-based prevention in Alabama, Kansas, and West Virginia. Kennedy said SAMHSA’s $12 million STREETS homelessness-and-addiction grants will carry a “new emphasis on faith-based recovery.” And a Justice Department legal opinion has struck down Biden-era rules that protected people from religious discrimination in federally funded programs. One message says medication shouldn’t be forever. The other sends money toward programs that already think so. Neither one, alone, requires anyone to come off buprenorphine. Together they make it easy.
HHS has already handed out $500,000 supplemental awards for faith-based prevention in Alabama, Kansas, and West Virginia.
Three months is not a treatment plan. It is a tolerance trap.
Here is the plain-language version of what happens when someone stops buprenorphine. While you take it every day, your body gets used to opioids, and that tolerance protects you. Stop, and the tolerance fades within days to weeks. Your cravings don’t fade that fast. If you use again, especially in a supply that is now mostly fentanyl, the dose that used to feel ordinary can stop your breathing. Clinicians call this “loss of tolerance.” People who have lived it call it the most dangerous week of the year.
The numbers back up the fear. In the largest study of people who stopped long-term buprenorphine, Arthur Robin Williams and colleagues at Columbia followed Medicaid patients after discontinuation and published the results in the American Journal of Psychiatry. Within six months, about 5% had a medically treated overdose. Between 42% and 50% ended up in an emergency room. Outcomes got better the longer people had been on the medication, but the improvement only became statistically meaningful after about 15 months. Even then, the authors wrote, risks stayed high. The study counted only overdoses that reached a hospital, so the real number is almost certainly higher. It also measured Medicaid patients who stopped for any reason, not people tapered slowly with a team behind them. That limit cuts both ways: it is not proof every taper fails, and it is no reason to believe a three-month taper is safe.
On the other side of the scale is what medication does while people are on it. Marc Larochelle and colleagues followed 17,568 Massachusetts adults who survived an opioid overdose and reported in the Annals of Internal Medicine that methadone was associated with a 59% drop in opioid-related deaths over the next year, and buprenorphine with a 38% drop. That is an observational study, not a randomized trial. It is also one of the clearest signals in addiction medicine, and it matches nearly everything that came after.
If you are on buprenorphine or methadone right now and someone has told you the goal is to get off it, here is what the research says, and what the program may not tell you. Stopping is not the same as recovering. Some people taper successfully, slowly, when their lives are steady and they want to. Many people stay on for years and build whole lives on top of that stability, the way someone with diabetes builds a life on insulin. Both are recovery. A rule that picks the date for you, before anyone knows how you’re doing, is not about your recovery. It is about the program’s beliefs. We wrote last week about people for whom a monthly buprenorphine shot gave them their mornings back. Under a three-month rule, those mornings come with an end date.
We have watched a health secretary praise faith and doubt medicine before
On May 9, 2017, Tom Price, then the HHS secretary, stood in Charleston, West Virginia, the state with the highest overdose death rate in the country, and said of medication treatment: “If we’re just substituting one opioid for another, we’re not moving the dial much.” The Charleston Gazette-Mail noted that he praised faith-based programs on the same trip, and that the one medication he spoke warmly about was Vivitrol, a monthly naltrexone shot that blocks opioids rather than replacing them. That pattern is worth naming, because it is back. The medicine that lets people abstain gets praised. The medicines with the strongest evidence for keeping people alive get treated as a problem to be managed down. More than 600 researchers and clinicians signed a letter asking him to correct the record. HHS said nothing had changed. In the five years that followed, America’s overdose deaths kept climbing, past 100,000 a year by 2021. Medication wasn’t why. But a government that spent those years apologizing for the treatment that worked did not help the people who needed it. Now the same idea is back, in softer words and with grant money attached.
In the five years that followed, America’s overdose deaths kept climbing, past 100,000 a year by 2021.
The difference this time is that the language is more polished and the mechanism is more concrete. Price only talked. This year’s version comes with grant terms and new funding streams. It also comes with a theory, openly stated by HHS, that faith-based groups can step in where government has stepped back. Libby Jones of the Global Health Advocacy Incubator told STAT that “there seems to be an expectation from the Trump administration that these faith-based groups” will fill the gaps left as people lose Medicaid coverage. That is a big job to hand to programs that, by STAT’s account of the research, are less likely than secular programs to offer medication and more likely to turn away people who take it.
Faith can stay. The taper clock has to go.
The fix is narrower than the fight makes it sound. Nobody serious is asking the government to defund prayer. Ayana Jordan, an addiction psychiatrist at NYU Langone who partners with faith organizations, told STAT that refusing patients on FDA-approved medications “is so irresponsible,” and that she would not fund centers if “they’re actively working against things that we know can save lives.” That is the line. Fund the church-basement program that keeps a bed for a man on buprenorphine. Don’t fund the one that sends him back to the street at day 91.
Sheepgate’s own regional president, Michael Hunsberger, may have pointed to the solution. He told STAT the center would accept patients on addiction medications if it had more funding and medical staff. Take him at his word. If federal dollars are going to faith-based recovery, attach one condition: accept people on methadone and buprenorphine at the dose their prescriber sets, for as long as the prescriber and patient decide. The grant notices for these programs already require “evidence-based practices.” Medication for opioid use disorder is the most evidence-based practice in the field. Enforce the rule that’s already written.
If you refer people to residential programs or recovery homes, you don’t have to wait for Washington. This week, add one question to your referral script and ask it before you send anyone: “Will you accept this person on methadone or buprenorphine at their current dose, with no taper deadline?” Get the answer in writing or in the intake notes. In Montgomery County, Ohio, two of the six Christian recovery homes funded by the local board turn away people on medication. The program’s website rarely says so. Sheepgate’s rule is spelled out in its men’s guidelines, but many programs only mention it at intake. If you run a SAMHSA-funded program, write the patient’s own preference into the annual medication review the grant terms now require. Then a “discussion” can’t quietly turn into a default.
If you’re on medication and worried, here is what is still yours tonight. Buprenorphine and methadone are still FDA-approved, still covered by Medicaid, and still the standard of care. SAMHSA’s own letter says arbitrary time limits and abrupt stops lead to “poor outcomes.” If a program tells you to taper on its schedule, you can quote that line back to them. And programs that will keep you on your medication do exist. Rize can help you find one that takes your insurance. You can also follow this fight on our policy and funding desk.
Mark Tassinari didn’t need a less religious program. He needed one that would let him keep his prescription and his bed. The country is about to spend real money deciding whether the next person in his position gets both.
Sources Cited
- 01.B
- 02.A
- 03.A
- 04.A
- 05.A
- 06.B
- 07.B
- 08.B
- 09.B
- 10.CSheepgate Men's GuidelinesSheepgate
Filed Under
policytreatmentpsychologySAMHSAFederalFundingMAT — BuprenorphineMAT — MethadoneRecovery HousingStigmaRelapse PreventionOverdosePeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.